Evidence map›Paper›PMID 31189713›Full record

ArticleJournal of virology2019

Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response.

Caroline Lehmann, Jessica Julia Falk, Nicole Büscher, Inessa Penner, Christine Zimmermann, Patricia Gogesch, Christian Sinzger, Bodo Plachter

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. The Pentamer glycoprotein complex inhibits viral Immediate Early transcription during Human Cytomegalovirus infections.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Caroline LehmannInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Jessica Julia FalkInstitute for Virology, Ulm University Medical Center, Ulm, Germany.
Nicole BüscherInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Inessa PennerInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Christine ZimmermannInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Patricia GogeschInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Christian SinzgerInstitute for Virology, Ulm University Medical Center, Ulm, Germany.
Bodo PlachterInstitute for Virology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany plachter@uni-mainz.de.
University Medical Center of the Johannes Gutenberg University Mainz · DEJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of a vaccine against human cytomegalovirus infection (HCMV) is a high-priority medical goal. The viral pentameric protein complex consisting of glycoprotein H (gH)/gL/UL128-131A (PC) is considered to be an important vaccine component. Its relevance to the induction of a protective antibody response is, however, still a matter of debate. We addressed this issue by using subviral dense bodies (DBs) of HCMV. DBs are exceptionally immunogenic. Laboratory HCMV strain DBs harbor important neutralizing antibody targets, like the glycoproteins B, H, L, M, and N, but they are devoid of the PC. To be able to directly compare the impact of the PC on the levels of neutralizing antibody (NT-abs) responses, a PC-positive variant of the HCMV laboratory strain Towne was established by bacterial artificial chromosome (BAC) mutagenesis (Towne-UL130rep). This strain synthesized PC-positive DBs upon infection of fibroblasts. These DBs were used in side-by-side immunizations with PC-negative Towne DBs. Mouse and rabbit sera were tested to address the impact of the PC on DB immunogenicity. The neutralizing antibody response to PC-positive DBs was superior to that of PC-negative DBs, as tested on fibroblasts, epithelial cells, and endothelial cells and for both animal species used. The experiments revealed the potential of the PC to enhance the antibody response against HCMV. Of particular interest was the finding that PC-positive DBs induced an antibody response that blocked the infection of fibroblasts by a PC-positive viral strain more efficiently than sera following immunizations with PC-negative particles.

Indexed as

AnimalsAntibodies, NeutralizingCells, CulturedCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesForeskinHumansHuman Umbilical Vein Endothelial CellsMaleMembrane GlycoproteinsMiceMultiprotein ComplexesRabbitsViral Envelope ProteinsAntibodies, NeutralizingCytomegalovirus Vaccinesglycoprotein H, Human cytomegalovirusMembrane GlycoproteinsMultiprotein ComplexesUL115 protein, Human herpesvirus 5UL128 protein, human cytomegalovirusUL130 protein, human cytomegalovirusViral Envelope Proteinscytomegalovirusdense bodiesgH/gL/UL128-131neutralizing antibodiespentamervaccine

Identifiers

PMID31189713
PMCPMC6694834
OpenAlexW2951644607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.